Literature DB >> 20694540

Vasoactive intestinal polypeptide relaxes isolated rat pulmonary artery rings through two distinct mechanisms.

Shuang Zhang1, Yun Liu, Shouli Guo, Jianing Zhang, Xiaojie Chu, Chun Jiang, Daling Zhu.   

Abstract

Vasoactive intestinal polypeptide (VIP), an endogenous neuropeptide normally present in lungs and other organs, relaxes pulmonary arteries (PAs) in different species, whereas the underlying mechanisms are still not fully understood. The aim of this study, therefore, is to investigate the signal transduction of VIP in the relaxation of isolated rat PA rings. The isometric tension of the rings was studied in vitro with force-electricity transducers. In endothelium-intact (EI) rings, VIP elicited concentration-dependent relaxation after the rings were pre-contracted by phenylephrine. A similar effect, though smaller, was observed in endothelium-denuded (ED) rings. Inhibition of the endothelial nitric oxide synthase (eNOS) by NG-nitro-L-arginine methyl ester diminished the VIP-induced vasodilatation of PA rings. The VIP-induced vasorelaxation was markedly reduced by the inhibition of the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway with wortmannin and LY294002, respectively, which was seen in EI rings, but not in ED rings. Western blot analysis revealed that VIP increased the phosphorylation of eNOS at Ser 1177, but did not affect the overall expression of eNOS. In ED rings, the PKA inhibitor H-89 and K(ATP) channel inhibitor glibenclamide almost totally abolished the vasodilatation effect of VIP. The results suggested that the vasodilatation effect of VIP on rat PAs is mediated by both vascular endothelium and smooth muscle, involving respectively the PI3K/Akt-eNOS pathway and the PKA-K(ATP) channel pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20694540     DOI: 10.1007/s12576-010-0107-x

Source DB:  PubMed          Journal:  J Physiol Sci        ISSN: 1880-6546            Impact factor:   2.781


  32 in total

Review 1.  Control of airway smooth muscle tone: II-pharmacology of relaxation.

Authors:  S Thirstrup
Journal:  Respir Med       Date:  2000-06       Impact factor: 3.415

Review 2.  Pulmonary arterial hypertension.

Authors:  Harrison W Farber; Joseph Loscalzo
Journal:  N Engl J Med       Date:  2004-10-14       Impact factor: 91.245

Review 3.  The regulation and pharmacology of endothelial nitric oxide synthase.

Authors:  David M Dudzinski; Junsuke Igarashi; Daniel Greif; Thomas Michel
Journal:  Annu Rev Pharmacol Toxicol       Date:  2006       Impact factor: 13.820

4.  15-hydroxyeicosatetraenoic acid depressed endothelial nitric oxide synthase activity in pulmonary artery.

Authors:  Hong Ye; Hai-Rong Bi; Chang-Lian Lü; Xiao-Bo Tang; Da-Ling Zhu
Journal:  Sheng Li Xue Bao       Date:  2005-10-25

5.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension.

Authors:  B W Christman; C D McPherson; J H Newman; G A King; G R Bernard; B M Groves; J E Loyd
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

6.  Neuronal and smooth muscle receptors involved in the PACAP- and VIP-induced relaxations of the pig urinary bladder neck.

Authors:  M Hernández; M V Barahona; P Recio; S Benedito; A C Martínez; L Rivera; A García-Sacristán; D Prieto; L M Orensanz
Journal:  Br J Pharmacol       Date:  2006-07-17       Impact factor: 8.739

7.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

Authors:  A Giaid; D Saleh
Journal:  N Engl J Med       Date:  1995-07-27       Impact factor: 91.245

8.  Vasoactive intestinal polypeptide relaxes pulmonary artery by an endothelium-independent mechanism.

Authors:  T Sata; H P Misra; E Kubota; S I Said
Journal:  Peptides       Date:  1986       Impact factor: 3.750

9.  Autoinhibition of endothelial nitric oxide synthase (eNOS) in gut smooth muscle by nitric oxide.

Authors:  John R Grider; Karnam S Murthy
Journal:  Regul Pept       Date:  2008-10-01

10.  Distribution of the VPAC2 receptor in peripheral tissues of the mouse.

Authors:  Anthony J Harmar; W John Sheward; Christine F Morrison; Beatrice Waser; Mathias Gugger; Jean Claude Reubi
Journal:  Endocrinology       Date:  2003-11-14       Impact factor: 4.736

View more
  5 in total

1.  Mechanisms of VIP-induced inhibition of the lymphatic vessel pump.

Authors:  Pierre-Yves von der Weid; Sonia Rehal; Peter Dyrda; Stewart Lee; Ryan Mathias; Mozibur Rahman; Simon Roizes; Mohammad S Imtiaz
Journal:  J Physiol       Date:  2012-03-25       Impact factor: 5.182

2.  Parasympathetic influences on emmetropization in chicks: evidence for different mechanisms in form deprivation vs negative lens-induced myopia.

Authors:  Debora L Nickla; Falk Schroedl
Journal:  Exp Eye Res       Date:  2012-07-22       Impact factor: 3.467

3.  VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression via a novel autocrine mechanism.

Authors:  Bo Tang; Jilin Wu; Michael X Zhu; Xuemei Sun; Jingjing Liu; Rui Xie; Tobias Xiao Dong; Yufeng Xiao; John M Carethers; Shiming Yang; Hui Dong
Journal:  Oncogene       Date:  2019-01-28       Impact factor: 9.867

4.  Shenfu Injection Promotes Vasodilation by Enhancing eNOS Activity Through the PI3K/Akt Signaling Pathway In Vitro.

Authors:  Jinqiang Zhu; Wanshan Song; Shixin Xu; Yan Ma; Baoyu Wei; Hongwu Wang; Shengyu Hua
Journal:  Front Pharmacol       Date:  2020-02-26       Impact factor: 5.810

5.  Inhibition of vascular smooth muscle growth via signaling crosstalk between AMP-activated protein kinase and cAMP-dependent protein kinase.

Authors:  Joshua D Stone; Avinash Narine; David A Tulis
Journal:  Front Physiol       Date:  2012-10-29       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.